| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P2093 | author name string | Tong Wang | |
| He Li | |||
| Gang Guo | |||
| Xuemei Dong | |||
| Zhiyu Chen | |||
| Bingying Xu | |||
| Chunting Wu | |||
| Yundan Liang | |||
| P2860 | cites work | A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24 | Q28271050 |
| Cytochrome p450 and chemical toxicology | Q33308211 | ||
| Warfarin-acetaminophen drug interaction revisited | Q33747163 | ||
| CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement | Q34026257 | ||
| CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis | Q34394876 | ||
| Common VKORC1 and GGCX polymorphisms associated with warfarin dose | Q34417386 | ||
| Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin | Q35204081 | ||
| The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors | Q35640455 | ||
| Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes | Q36044022 | ||
| CYP4F2 polymorphism as a genetic risk factor for major hemorrhagic complications in Chinese patients on warfarin therapy | Q36163728 | ||
| Prediction of warfarin dose: why, when and how? | Q37989489 | ||
| Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. | Q39862947 | ||
| Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention | Q40844377 | ||
| Warfarin pharmacogenetics: polymorphisms of the CYP2C9, CYP4F2, and VKORC1 loci in a genetically admixed Omani population. | Q42641618 | ||
| Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients | Q42722677 | ||
| Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations | Q42791847 | ||
| Genetic determinants of warfarin dosing in the Han-Chinese population | Q43230870 | ||
| Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy | Q43942672 | ||
| Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. | Q44259188 | ||
| Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin | Q44787224 | ||
| Chromosomal localization of the gamma-glutamyl carboxylase gene at 2p12. | Q46090079 | ||
| The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers | Q46797039 | ||
| Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. | Q51906199 | ||
| High-resolution SNP and haplotype maps of the human gamma-glutamyl carboxylase gene (GGCX) and association study between polymorphisms in GGCX and the warfarin maintenance dose requirement of the Japanese population. | Q51906653 | ||
| Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. | Q52005905 | ||
| Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. | Q53248119 | ||
| VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. | Q53251775 | ||
| Genomic sequence and transcription start site for the human gamma-glutamyl carboxylase | Q73374135 | ||
| Genetic association between sensitivity to warfarin and expression of CYP2C9*3 | Q73834859 | ||
| CYP2C19 polymorphism in Korean patients on warfarin therapy | Q80137530 | ||
| Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose | Q80977030 | ||
| The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement | Q83290003 | ||
| P433 | issue | 12 | |
| P921 | main subject | (RS)-warfarin | Q407431 |
| P304 | page(s) | 932-936 | |
| P577 | publication date | 2013-08-13 | |
| P1433 | published in | Genetic Testing and Molecular Biomarkers | Q15753742 |
| P1476 | title | Association of genetic polymorphisms with warfarin dose requirements in Chinese patients | |
| P478 | volume | 17 |
| Q37606335 | Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement |
| Q43113299 | Genetic determinants of variability in warfarin response after the dose-titration phase. |
| Q28071310 | Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis |
| Q35757323 | Impact of polymorphisms of the GGCX gene on maintenance warfarin dose in Chinese populations: Systematic review and meta-analysis |
| Q36742224 | Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysis |
| Q41824237 | Influence of two common polymorphisms in the EPHX1 gene on warfarin maintenance dosage: a meta-analysis |
| Q57500191 | The association between GGCX, miR-133 genetic polymorphisms and warfarin stable dosage in Han Chinese patients with mechanical heart valve replacement |
| Q39066100 | Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients. |
Search more.